Headlines
US approves AstraZeneca, Daiichi's treatment for lung cancer
Published by Global Banking and Finance Review
Posted on June 24, 2025
Global Banking and Finance Review
Company
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking and Finance Review
Posted on June 24, 2025
(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this indication and expanding access for patients.
Datroway has been approved in the United States, the world's biggest pharmaceuticals market, to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment, AstraZeneca said on Tuesday, adding it was the first such therapy to get the greenlight there for treating lung cancer.
Datroway belongs to a class of medicines called antibody-drug conjugates, also known as "guided-missiles" because they are designed to target only cancer cells while sparing healthy cells, unlike conventional chemotherapy.
It works by targeting the TROP2 protein found on the surface of tumour cells of many types of cancer, and is already approved for treating a form of breast cancer.
"This first approval of Datroway in lung cancer provides a much-needed option to patients with advanced EGFR-mutated lung cancer whose disease has become resistant to past treatments, regardless of the driving mutation," AstraZeneca executive Dave Fredrickson said, referring to the specifics of the latest approval.
AstraZeneca and Japan's Daiichi have a long-standing collaboration for developing cancer therapies, beginning first with Enhertu and then an agreement in 2020 to jointly develop and commercialize what is now Datroway in a deal worth up to $6 billion.
The Anglo-Swedish drugmaker on Tuesday said it would pay Daiichi $45 million in milestone-related considerations following the U.S. approval.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Sonia Cheema)